Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.


The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page


My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1945 2
1946 4
1947 2
1948 6
1949 2
1950 5
1951 8
1952 3
1953 1
1954 3
1955 5
1956 2
1957 1
1958 2
1960 2
1961 1
1962 3
1963 3
1964 1
1965 1
1967 1
1968 1
1969 1
1970 1
1971 2
1972 2
1978 3
1979 5
1981 2
1982 4
1983 6
1984 6
1985 8
1986 6
1987 5
1988 10
1989 3
1990 6
1991 6
1992 5
1993 8
1994 6
1995 2
1996 4
1997 5
1998 10
1999 7
2000 11
2001 8
2002 14
2003 7
2004 8
2005 12
2006 11
2007 18
2008 15
2009 14
2010 18
2011 18
2012 19
2013 20
2014 23
2015 18
2016 26
2017 25
2018 34
2019 31
2020 37
2021 47
2022 44
2023 27

Text availability

Article attribute

Article type

Publication date

Search Results

627 results

Results by year

Filters applied: . Clear all
Page 1
Anti-NKG2A mAb Is a Checkpoint Inhibitor that Promotes Anti-tumor Immunity by Unleashing Both T and NK Cells.
André P, Denis C, Soulas C, Bourbon-Caillet C, Lopez J, Arnoux T, Bléry M, Bonnafous C, Gauthier L, Morel A, Rossi B, Remark R, Breso V, Bonnet E, Habif G, Guia S, Lalanne AI, Hoffmann C, Lantz O, Fayette J, Boyer-Chammard A, Zerbib R, Dodion P, Ghadially H, Jure-Kunkel M, Morel Y, Herbst R, Narni-Mancinelli E, Cohen RB, Vivier E. André P, et al. Among authors: morel a. Cell. 2018 Dec 13;175(7):1731-1743.e13. doi: 10.1016/j.cell.2018.10.014. Epub 2018 Nov 29. Cell. 2018. PMID: 30503213 Free PMC article. Review.
Multifunctional Natural Killer Cell Engagers Targeting NKp46 Trigger Protective Tumor Immunity.
Gauthier L, Morel A, Anceriz N, Rossi B, Blanchard-Alvarez A, Grondin G, Trichard S, Cesari C, Sapet M, Bosco F, Rispaud-Blanc H, Guillot F, Cornen S, Roussel A, Amigues B, Habif G, Caraguel F, Arrufat S, Remark R, Romagné F, Morel Y, Narni-Mancinelli E, Vivier E. Gauthier L, et al. Among authors: morel a. Cell. 2019 Jun 13;177(7):1701-1713.e16. doi: 10.1016/j.cell.2019.04.041. Epub 2019 May 30. Cell. 2019. PMID: 31155232 Free article. Review.
Genomics to select treatment for patients with metastatic breast cancer.
Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc F, Sablin MP, Campone M, Bonnefoi H, Lefeuvre-Plesse C, Jacot W, Coussy F, Ferrero JM, Emile G, Mouret-Reynier MA, Thery JC, Isambert N, Mege A, Barthelemy P, You B, Hajjaji N, Lacroix L, Rouleau E, Tran-Dien A, Boyault S, Attignon V, Gestraud P, Servant N, Le Tourneau C, Cherif LL, Soubeyran I, Montemurro F, Morel A, Lusque A, Jimenez M, Jacquet A, Gonçalves A, Bachelot T, Bieche I. Andre F, et al. Among authors: morel a. Nature. 2022 Oct;610(7931):343-348. doi: 10.1038/s41586-022-05068-3. Epub 2022 Sep 7. Nature. 2022. PMID: 36071165 Clinical Trial.
Antitumor immunity induced by antibody-based natural killer cell engager therapeutics armed with not-alpha IL-2 variant.
Demaria O, Gauthier L, Vetizou M, Blanchard Alvarez A, Vagne C, Habif G, Batista L, Baron W, Belaïd N, Girard-Madoux M, Cesari C, Caratini M, Bosco F, Benac O, Lopez J, Fenis A, Galluso J, Trichard S, Carrette B, Carrette F, Maguer A, Jaubert S, Sansaloni A, Letay-Drouet R, Kosthowa C, Lovera N, Dujardin A, Chanuc F, Le Van M, Bokobza S, Jarmuzynski N, Fos C, Gourdin N, Remark R, Lechevallier E, Fakhry N, Salas S, Deville JL, Le Grand R, Bonnafous C, Vollmy L, Represa A, Carpentier S, Rossi B, Morel A, Cornen S, Perrot I, Morel Y, Vivier E. Demaria O, et al. Among authors: morel a. Cell Rep Med. 2022 Oct 18;3(10):100783. doi: 10.1016/j.xcrm.2022.100783. Cell Rep Med. 2022. PMID: 36260981 Free PMC article.
Control of acute myeloid leukemia by a trifunctional NKp46-CD16a-NK cell engager targeting CD123.
Gauthier L, Virone-Oddos A, Beninga J, Rossi B, Nicolazzi C, Amara C, Blanchard-Alvarez A, Gourdin N, Courta J, Basset A, Agnel M, Guillot F, Grondin G, Bonnevaux H, Bauchet AL, Morel A, Morel Y, Chiron M, Vivier E. Gauthier L, et al. Among authors: morel a. Nat Biotechnol. 2023 Sep;41(9):1296-1306. doi: 10.1038/s41587-022-01626-2. Epub 2023 Jan 12. Nat Biotechnol. 2023. PMID: 36635380 Free PMC article.
In reply.
Boisdron-Celle M, Capitain O, Faroux R, Borg C, Philippe Metges J, Galais MP, Kaassis M, Bennouna J, Bouhier-Leporrier K, Francois E, Baumgaertner I, Guerin-Meyer V, Cojocarasu O, Roemer-Becuwe C, Stampfli C, Rosenfeld L, Lecompte T, Berger V, Morel A, Gamelin E. Boisdron-Celle M, et al. Among authors: morel a. Semin Oncol. 2017 Apr;44(2):161. doi: 10.1053/j.seminoncol.2017.08.002. Epub 2017 Aug 4. Semin Oncol. 2017. PMID: 28923216 No abstract available.
Methylphenidate and stuttering.
Trenque T, Claustre G, Herlem E, Djerada Z, Trenque A, Morel A, Azzouz B. Trenque T, et al. Among authors: morel a. Br J Clin Pharmacol. 2019 Nov;85(11):2634-2637. doi: 10.1111/bcp.14097. Epub 2019 Sep 12. Br J Clin Pharmacol. 2019. PMID: 31418914 Free PMC article.
Morel AF, Gonzaga Wde A, Burrow RA, Maichle-Mössmer C, Strähle J. Morel AF, et al. Acta Crystallogr C. 2002 Oct;58(Pt 10):o606-7. doi: 10.1107/s0108270102015202. Epub 2002 Sep 30. Acta Crystallogr C. 2002. PMID: 12359942
[Oxaliplatin neurotoxicity].
Gamelin L, Boisdron-Celle M, Morel A, Gamelin E. Gamelin L, et al. Among authors: morel a. Bull Cancer. 2006 Feb 1;93 Suppl 1:S17-22. Bull Cancer. 2006. PMID: 16491518 Review. French.
[Lower-limb peripheral arterial disease].
Le Hello C, Fouillet L, Boulon C, Rivière S, El Jaouhari A, Seffert B, Morel A, Boissier C. Le Hello C, et al. Among authors: morel a. Rev Med Interne. 2020 Oct;41(10):667-672. doi: 10.1016/j.revmed.2020.03.009. Epub 2020 Apr 30. Rev Med Interne. 2020. PMID: 32359979 Review. French.
627 results